Orchard Therapeutics Plc (ORTX)

11.53
0.17 1.50
NASDAQ : Health Technology
Prev Close 11.36
Open 11.36
Day Low/High 11.33 / 11.72
52 Wk Low/High 8.65 / 21.64
Volume 93.20K
Avg Volume 200.40K
Exchange NASDAQ
Shares Outstanding 94.87M
Market Cap 1.11B
EPS -10.20
Div & Yield N.A. (N.A)

Latest News

Orchard Therapeutics To Present At The 2019 Cell & Gene Meeting On The Mesa

Orchard Therapeutics To Present At The 2019 Cell & Gene Meeting On The Mesa

BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics Announces Departure Of Chief Commercial Officer

Orchard Therapeutics Announces Departure Of Chief Commercial Officer

BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics Announces Encouraging Update From Proof-of-Concept Study Of OTL-203 For The Treatment Of Mucopolysaccharidosis Type I (MPS-I)

Orchard Therapeutics Announces Encouraging Update From Proof-of-Concept Study Of OTL-203 For The Treatment Of Mucopolysaccharidosis Type I (MPS-I)

Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment Evidence of Engraftment and Peripheral Blood Alpha-L-iduronidase (IDUA) Enzyme Overexpression Across Cohort BOSTON and LONDON, Sept.

Orchard Therapeutics Presents An Integrated Data Analysis Demonstrating Sustained Clinical Benefit Of OTL-200 For The Treatment Of Metachromatic Leukodystrophy

Orchard Therapeutics Presents An Integrated Data Analysis Demonstrating Sustained Clinical Benefit Of OTL-200 For The Treatment Of Metachromatic Leukodystrophy

Further Demonstration that OTL-200 Provides Meaningful Clinical Benefit on Cognitive and Motor Function No Standard Treatment Options Available, Regulatory Submission in Europe Planned for First Half of 2020 and U.

Orchard Therapeutics To Webcast Presentation At The Morgan Stanley 17th Annual Global Healthcare Conference

Orchard Therapeutics To Webcast Presentation At The Morgan Stanley 17th Annual Global Healthcare Conference

BOSTON and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics Further Strengthens Board Of Directors With Appointment Of John Curnutte, M.D., Ph.D.

Orchard Therapeutics Further Strengthens Board Of Directors With Appointment Of John Curnutte, M.D., Ph.D.

BOSTON and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics Announces Presentation Of Data From Neurometabolic Portfolio At Upcoming Society For The Study Of Inborn Errors Of Metabolism (SSIEM) 2019 Annual Symposium

Orchard Therapeutics Announces Presentation Of Data From Neurometabolic Portfolio At Upcoming Society For The Study Of Inborn Errors Of Metabolism (SSIEM) 2019 Annual Symposium

Mucopolysaccharidosis Type I and Metachromatic Leukodystrophy Abstracts Accepted for Oral Presentations

Orchard Therapeutics Reports Second Quarter 2019 Financial Results And Builds Momentum Ahead Of Regulatory Filings

Orchard Therapeutics Reports Second Quarter 2019 Financial Results And Builds Momentum Ahead Of Regulatory Filings

Metachromatic Leukodystrophy (MLD) MAA Submission and Initiation of ADA-SCID Rolling BLA Expected in the First Half of 2020; OTL-103 Recently Granted RMAT Designation for Wiskott-Aldrich Syndrome (WAS) MLD and Mucopolysaccharidosis Type I (MPS-I)...

Orchard Therapeutics To Webcast Presentation At The 2019 Wedbush PacGrow Healthcare Conference

Orchard Therapeutics To Webcast Presentation At The 2019 Wedbush PacGrow Healthcare Conference

BOSTON and LONDON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics To Webcast Conference Call Of Second Quarter 2019 Financial Results

Orchard Therapeutics To Webcast Conference Call Of Second Quarter 2019 Financial Results

BOSTON and LONDON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through...

Orchard Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted For OTL-103 For The Treatment Of Wiskott-Aldrich Syndrome

Orchard Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted For OTL-103 For The Treatment Of Wiskott-Aldrich Syndrome

Three-Year Registrational Data Set to be Presented by Year End 2019 Regulatory Submissions Planned in the U.